Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a background update to the site or content-management system.SummaryDifference0.0%

- Check16 days agoChange DetectedAn NIH grant/contract line for 2019 was added, and a new publication citation (Regnault et al., 2024) regarding tolerability in LIBRETTO-531 was also added.SummaryDifference0.0%

- Check30 days agoChange DetectedA new Revision: v3.6.5 was added and the previous Revision: v3.6.4 was removed, indicating a minor update to the page's version metadata.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page revision label was updated from Revision: v3.6.3 to Revision: v3.6.4, indicating a small frontend update to the study details page. This change does not modify study content or data.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page shows a new revision tag: v3.6.3, replacing the previous v3.6.1. This indicates a newer version of the page content.SummaryDifference0.0%

- Check80 days agoChange DetectedRevision: v3.6.1 is now displayed, replacing the previous v3.6.0. This reflects a frontend version update and does not modify study details or content on the page.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.